Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
RIPK1 inhibitor
Necrostatin-1 is an ATP-competitive, allosteric inhibitor of receptor-interacting protein kinase 1 (RIPK1) (EC50 = 182 nM).- Cheng Chen, .et al. , Neurochem Res, 2025, Mar 18;50(2):122 PMID: 40100474
- Binjie Yan, .et al. , Cell Death Discov, 2023, 9: 456 PMID: 38097554
-
RIPK3 Inhibitor
GSK-872 hydrochloride is a potent inhibitor of receptor-interacting protein kinase 3 (RIPK3), exhibiting an IC50 of 1.8 nM for binding to the RIP3 kinase domain and an IC50 of 1.3 nM for inhibiting its kinase activity. This compound effectively reduces RIPK3-mediated necroptosis and inhibits the cytoplasmic translocation and expression of HMGB1. Additionally, GSK-872 hydrochloride has been shown to alleviate brain edema and neurological deficits in models of early brain injury, making it a valuable tool for studying necroptosis and related pathophysiological processes. -
RIPK1 Inhibitor
TP-030-1 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1). It demonstrates a high affinity for human RIPK1 with a Ki value of 3.9 nM and an IC50 of 4.2 μM for mouse RIPK1. This compound is valuable for investigating the mechanisms underlying inflammatory and neurodegenerative diseases, providing insights into potential therapeutic interventions. -
RIPK2 Inhibitor
CSLP37 is a selective inhibitor of receptor-interacting protein kinase 2 (RIPK2), exhibiting an IC50 of 16.3 nM. This compound effectively suppresses cellular responses mediated by NOD1 and NOD2, while showing no significant inhibitory activity against RIPK1 and RIPK3. CSLP37 is a valuable tool for research into inflammatory signaling pathways and the role of RIPK2 in various diseases. -
RIPK1 Inhibitor
Cl-Necrostatin-1 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1). It effectively blocks TNF-α-induced necroptosis in Jurkat cells lacking FADD, with an EC50 of 180 nM, thereby preventing caspase activation linked to death-domain receptor signaling. Additionally, Cl-Necrostatin-1 has been shown to decrease infarct size in a mouse model of middle cerebral artery occlusion (MCAO), making it a valuable tool for research in cardiovascular and cerebrovascular pathologies. -
RIPK1 Inhibitor
ZB-R-55 is a potent orally active inhibitor of receptor-interacting protein kinase 1 (RIPK1). This compound exhibits significant potential in modulating cell death pathways and inflammation, making it a valuable tool for researching sepsis and other inflammatory conditions. Its ability to selectively inhibit RIPK1 supports investigations into therapeutic strategies for diseases characterized by dysregulated necroptosis. -
RIPK3 Inhibitor
RIPK3-IN-3 is a selective inhibitor of the receptor-interacting protein kinase 3 (RIPK3), with an IC50 of 10 nM. This compound effectively prevents the phosphorylation of Mixed Lineage Kinase (MLKL), thereby inhibiting oligomerization of p-MLKL and subsequently blocking necroptosis. Additionally, RIPK3-IN-3 has been shown to downregulate CXCL5 secretion and suppress migration and invasion in AsPC-1 cancer cells, making it a valuable tool for studying necroptosis and related pathways in cancer research. -
RIPK1 Inhibitor
TP-030-2 is a potent RIPK1 inhibitor, with a human Ki of 0.43 nM and a mouse IC50 of 100 nM. This compound is designed for research applications targeting necroptosis and inflammatory pathways, making it a valuable tool for investigating cell death mechanisms and disease processes related to RIPK1 signaling. Its high specificity and efficacy support investigations into therapeutic strategies for conditions involving dysregulated cell death. -
RIPK1 Inhibitor
SZM679 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) with a Kd value of 8.6 nM, demonstrating high specificity over RIPK3 (>5000 nM). This compound effectively reverses tumor necrosis factor-induced systemic inflammatory responses and reduces Tau hyperphosphorylation and neuroinflammation in the hippocampus and cortex. SZM679 has significant potential for research applications in Alzheimer's disease and other neurodegenerative disorders. -
RIPK1 Inhibitor
Necrostatin-34 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1). It stabilizes the inactive conformation of RIPK1 by binding to a specific pocket within the kinase domain, thereby preventing its activation. This compound is primarily utilized in research to explore necroptosis and cell death pathways, making it valuable for studies in inflammation, neurodegeneration, and cancer. -
RIPK1 Inhibitor
RI-962 is a potent and selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an IC50 value of 35.0 nM. This compound is applicable in research focused on neurodegenerative disorders and inflammatory diseases, where modulation of RIPK1 activity can provide insights into disease mechanisms and potential therapeutic strategies. -
RIPK2/ALK2 Inhibitor
OD36 hydrochloride is a potent inhibitor of receptor-interacting protein kinase 2 (RIPK2) and an effective modulator of activin receptor-like kinase 2 (ALK2), exhibiting an IC50 of 5.3 nM against RIPK2. This macrocyclic compound demonstrates strong binding affinity for the ALK2 kinase ATP pocket, with a Kd of 37 nM. OD36 hydrochloride is suitable for research applications focused on signaling pathways involving RIPK2 and ALK2, relevant in studying various diseases, including inflammation and cancer. -
RIPK1 Inhibitor
AV123 is a potent RIPK1 inhibitor with an IC50 of 12.12 µM. This non-cytotoxic compound effectively blocks TNF-α-induced necroptosis, exhibiting an EC50 of 1.7 µM, while leaving apoptotic pathways unaffected. AV123 is valuable for investigating necrotic conditions, including ischemia-reperfusion injuries in the brain, heart, and kidney, as well as in various inflammatory and neurodegenerative diseases. -
RIPK1 Inhibitor
Oditrasertib is a selective reversible inhibitor of receptor-interacting protein kinase 1 (RIPK1), demonstrating oral bioavailability and the ability to penetrate the blood-brain barrier. It is primarily utilized in research related to chronic inflammatory diseases of the central nervous system, including amyotrophic lateral sclerosis and multiple sclerosis. Oditrasertib provides valuable insights into the mechanisms of RIPK1-mediated signaling pathways, aiding in the development of potential therapeutic strategies for these conditions. -
RIPK1 Inhibitor
Eclitasertib is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an IC50 of 0.0375 µM. This compound is crucial for studying signaling pathways related to inflammation and cell death, making it valuable for research applications in apoptosis, neurodegeneration, and autoimmune diseases. Eclitasertib provides an effective tool for elucidating the role of RIPK1 in various biological contexts. -
RIPK3 Inhibitor
UH15-38 is a potent inhibitor of receptor-interacting protein kinase 3 (RIPK3), exhibiting an IC50 of 20 nM. This compound effectively blocks necroptosis activated by influenza A virus (IAV), reducing associated cellular damage. UH15-38 is valuable for research aimed at understanding viral pathogenesis and investigating potential therapeutic approaches for IAV-induced lung injury. -
RIPK3 Inhibitor
GSK840 is a highly potent inhibitor of receptor-interacting protein kinase 3 (RIPK3), exhibiting an IC50 of 0.9 nM for binding to the RIP3 kinase domain and an IC50 of 0.3 nM for inhibiting its kinase activity. This compound provides a valuable tool for studying RIPK3-mediated pathways and their role in programmed cell death and inflammation. GSK840 is applicable in research focused on neurodegenerative diseases, cancer, and immune responses. -
RIPK1/RIPK3 Inhibitor
RIPK1-IN-17 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) with a Kd of 17 nM, exhibiting minimal activity against RIPK3. This compound specifically targets necroptosis by inhibiting the phosphorylation of RIPK1, RIPK3, and MLKL, thereby preventing necroptotic cell death while allowing apoptosis to proceed. RIPK1-IN-17 has demonstrated protective effects in mice against hypothermia and mortality, making it a valuable tool for researching necroptosis-related conditions, particularly in the context of inflammatory response syndrome (SIRS). -
RIPK1 Inhibitor
Zharp1-211 is a selective inhibitor of RIPK1 kinase, with an EC50 of 53 nM and a Kd of 8.7 nM. This compound effectively reduces IFN-γ-induced STAT1 activation, presenting significant implications for the study of inflammatory responses. Zharp1-211 is suitable for research applications related to graft-versus-host disease and colon cancer, contributing to investigations into therapeutic strategies for these conditions. -
RIPK2 Inhibitor
Zharp2-1 is a potent inhibitor of receptor-interacting protein kinase 2 (RIPK2), which plays a critical role in inflammatory responses. This compound is particularly relevant in the context of inflammatory bowel disease (IBD), demonstrating the ability to modulate immune cell activation in response to muramyl dipeptide (MDP). Zharp2-1 effectively reduces MDP-induced small inguinal peritonitis and alleviates inflammation associated with DNBS-induced large inguinal conjunctivitis, making it a valuable tool for research in models of chronic inflammation and IBD. -
RIPK3 Inhibitor
RIPK3-IN-4 is a potent inhibitor of receptor-interacting protein kinase 3 (RIPK3), primarily known for its role in necroptosis and inflammation. This compound effectively protects HK-2 cells from damage, mitigating necroptosis and inflammatory responses. Additionally, RIPK3-IN-4 demonstrates significant protective effects against kidney damage induced by Cisplatin and ischemia/reperfusion, making it a valuable tool for research into acute kidney injury and related inflammatory conditions. -
RIPK3 Inhibitor
RIPK3-IN-6 is a type I inhibitor targeting Receptor-Interacting Serine/Threonine Kinase 3 (RIPK3), known for its role in programmed necrosis and inflammation. This compound exhibits poor selectivity across the RIPK family, particularly affecting the activity of RIPK2. It serves as a valuable tool for investigating necroptosis pathways and their implications in various diseases, providing insights into signaling processes and therapeutic targets. -
RIPK1 Inhibitor
SZM-1209 is a potent and specific inhibitor of RIPK1, demonstrating a Kd of 85 nM. It exhibits significant anti-necroptotic activity with an EC50 value of 22.4 ± 8.1 nM. SZM-1209 has been shown to mitigate conditions associated with systemic inflammatory response syndrome (SIRS) and acute lung injury (ALI), making it a valuable tool for research in inflammation-related pathologies. -
RIPK2/ALK2 Inhibitor
OD36 is a selective inhibitor of RIPK2 with an IC50 of 5.3 nM, demonstrating potent binding affinity to the ATP pocket of the ALK2 kinase, with a KD of 37 nM. This macrocyclic compound exhibits specific ALK2-directed activity, making it a valuable tool for investigating the roles of these kinases in various biological pathways. Research applications include the exploration of inflammatory signaling and potential therapeutic interventions in related diseases. -
RIPK1 Inhibitor
Ocadusertib is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), which plays a crucial role in cell survival and necroptosis signaling pathways. This compound is utilized in research applications investigating the regulation of programmed cell death and inflammation. Ocadusertib may provide insights into therapeutic strategies for diseases associated with dysregulated RIPK1 activity. -
RIPK3 Inhibitor
RIPK3-IN-1 is a selective inhibitor of receptor-interacting protein kinases 3 (RIPK3), functioning as a type II DFG-out inhibitor with an IC50 of 9.1 nM. This compound also exhibits inhibitory activity against RIPK1 and RIPK2, with IC50 values of 5.5 μM and >10 μM, respectively. Additionally, RIPK3-IN-1 serves as a c-Met kinase inhibitor, demonstrating an IC50 of 1.1 μM. It is suitable for studies related to necroptosis, cell signaling pathways, and cancer research applications. -
RIPK1 Inhibitor
Sibiriline is a selective competitive inhibitor of receptor-interacting protein kinase 1 (RIPK1), specifically targeting its ATP-binding site to stabilize the enzyme in an inactive state. This compound effectively inhibits TNF-induced RIPK1-dependent necroptosis and apoptosis, while sparing caspase-dependent apoptosis. Additionally, Sibiriline has demonstrated protective effects in murine models of concanavalin A-induced hepatitis, highlighting its potential for research in immune-mediated liver injury and related therapeutic applications. -
RIPK1 Inhibitor
RIPK1-IN-26 is a potent inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), exhibiting strong anti-necroptosis activity. This compound displays favorable metabolic stability and binding specificity in murine models. Its unique properties make RIPK1-IN-26 a valuable tool for investigating potential therapeutic applications in neurodegenerative disorders and developing PET imaging probes. -
RIPK1 Inhibitor
RIPK1-IN-23 is a selective inhibitor of Receptor Interacting Protein Kinase 1 (RIPK1), exhibiting potent anti-necroptotic effects with an EC50 of 1.7 nM in HT-29 cells. This compound also demonstrates significant anti-inflammatory activity, making it a valuable tool for investigating necroptosis and its associated inflammatory pathways in various biological research applications. -
RIPK1 Inhibitor
RIPK1-IN-18 sulfate hydrate is a highly selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), a key regulator of cell death and inflammation. Its potent inhibitory activity makes it a valuable reagent for research focused on autoimmune diseases, providing insights into the mechanistic pathways involved in such conditions. Additionally, RIPK1-IN-18 can be used to investigate the therapeutic potential of targeting RIPK1 in various inflammatory disorders. -
PROTAC-based RIP2 inhibitor
RIPK2-IN-2 is a PROTAC-based inhibitor specifically targeting RIP2 kinase. It effectively inhibits RIP2-dependent proinflammatory signaling pathways, thereby regulating RIP2 activity implicated in autoinflammatory diseases. This compound serves as a valuable tool for research in understanding the molecular mechanisms of inflammation and developing potential therapeutic strategies for related disorders. -
RIPK1 Inhibitor
RIPK1-IN-15 is a potent inhibitor of Receptor Interacting Protein Kinase 1 (RIPK1). This compound demonstrates significant potential in modulating pathways associated with neurodegenerative, autoimmune, and inflammatory diseases. Research applications include the investigation of cell death signaling, inflammation regulation, and therapeutic approaches targeting RIPK1-mediated pathologies. -
RIPK2/ALK2 Inhibitor
RIPK2-IN-1 is a selective inhibitor targeting RIPK2 and ALK2, with an IC50 of 51 nM and 5 nM, respectively. This compound demonstrates substantial efficacy in modulating RIPK2/NOD2 pathways, exhibiting an IC50 of 390 nM in cellular assays. RIPK2-IN-1 is suitable for research applications investigating pathways related to inflammation and immune response mechanisms. -
RIPK1 Inhibitor
RIPK1-IN-39 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an IC50 value of 69.40 nM and more than 100-fold selectivity over RIPK3 (IC50 = 6946 nM). This compound effectively prevents necroptosis in HT-22 and HT-29 cell lines by inhibiting the phosphorylation and activation of the RIPK1-RIPK3-MLKL signaling pathway. Additionally, RIPK1-IN-39 has demonstrated neuroprotective effects in a rat model of middle cerebral artery occlusion (MCAO), making it a valuable tool for research in acute ischemic stroke (AIS). -
RIPK2 Inhibitor
RIPK2-IN-8 is a selective inhibitor of Receptor-interacting protein kinase 2 (RIPK2) with an IC50 of 11 nM. It shows significant selectivity for RIPK2 over RIPK1 (IC50 > 30,000 nM) and a moderate inhibitory effect on RIPK3 (IC50 = 44.61 nM). By inhibiting the NOD2-RIPK2 signaling pathway, RIPK2-IN-8 reduces the expression of key inflammatory cytokines such as IL-6 and TNFα, demonstrating robust anti-inflammatory properties. Its efficacy in an acute liver injury model indicates potential applications in liver injury and inflammation research. -
RIPK1 Inhibitor
RIPK1-IN-21 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an EC50 value of 14.8 nM. This compound is valuable for research into neurodegenerative, autoimmune, and inflammatory diseases, where modulation of RIPK1 activity may play a critical role. Its potent inhibitory effects enable investigations into the mechanisms of RIPK1-mediated cell death and inflammation. -
RIPK2 Inhibitor
RIPK2-IN-3 is a potent inhibitor of Receptor Interacting Protein Kinase 2 (RIPK2), demonstrating an IC50 of 6.39 μM against recombinant truncated RIPK2. This compound is utilized in research studies focused on inflammation and cancer, providing valuable insights into the pathways regulated by RIPK2. Its specificity makes it a useful tool for evaluating RIPK2's role in various biological processes. -
RIPK1 Inhibitor
RIPK1-IN-14 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an IC50 value of 92 nM. This compound demonstrates significant anti-necroptotic effects in a necroptosis model utilizing U937 cells. RIPK1-IN-14 is applicable in research focusing on cell death mechanisms, inflammation, and neurodegenerative diseases. -
RIPK1 Inhibitor
RIPK1-IN-28 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1). It demonstrates significant biological activity with IC50 values of 0.4 nM and 1.2 nM against human I2.1 and Hepa1-6 cell lines, respectively. This compound is valuable for research applications aimed at elucidating the role of RIPK1 in cell death and inflammatory processes. -
RIPK1 Inhibitor
RIPK1-IN-12 is a potent inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). It effectively inhibits necroptosis, with EC50 values of 1.6 nM in human cells and 2.9 nM in mouse cells. This compound is valuable for research applications focused on cell death pathways and related diseases such as neurodegeneration and cancer. -
RIPK1 Inhibitor
RIPK1-IN-11 is a potent and orally active inhibitor of receptor-interacting protein kinase 1 (RIPK1), demonstrating a Kd of 9.2 nM and an IC50 of 67 nM. This compound effectively inhibits necroptosis in human and mouse cells, with an EC50 range of 17-30 nM. Due to its anti-inflammatory properties, RIPK1-IN-11 is valuable in researching the pathophysiology of inflammatory diseases and cell death mechanisms. -
RIPK1 Inhibitor
RIPK1-IN-38 is a potent, orally active inhibitor of receptor-interacting protein kinase 1 (RIPK1), with an IC50 value of 27 nM. It effectively blocks the phosphorylation of RIPK1 and its downstream effectors, RIPK3 and MLKL, thereby exhibiting significant anti-necroptotic activity. This compound demonstrates strong anti-inflammatory effects in models of systemic inflammatory response syndrome (SIRS) and graft-versus-host disease (GVHD). RIPK1-IN-38 is suitable for research into inflammatory and immune-related diseases. -
RIPK1 Inhibitor
RIPK1-IN-13 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1), exhibiting an IC50 value of 1139 nM. By inhibiting RIPK1, this compound effectively disrupts the necroptosis pathway, making it a valuable tool for investigating the molecular mechanisms underlying inflammatory diseases. Its applications extend to various research areas focused on cell death and inflammatory processes. -
RIPK1 Inhibitor
RIPK1-IN-18 is a selective inhibitor of Receptor-Interacting Protein Kinase 1 (RIPK1). It demonstrates potent activity in modulating cell death and inflammation pathways, making it a valuable tool for investigating the underlying mechanisms of autoimmune diseases. This compound is applicable in research focused on therapeutic strategies for conditions associated with RIPK1-mediated signaling. -
RIPK1 Inhibitor
RIPK1-IN-37 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1), which plays a crucial role in apoptosis and inflammation. This compound serves as a ligand for the target protein in the PROTAC LD5097 synthesis, facilitating targeted protein degradation research. Its application extends to studies of cell death pathways and the development of novel therapeutics for diseases involving dysregulated RIPK1 activity. -
RIPK1 Inhibitor
RIPK1-IN-34 is a selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an IC50 of 126.70 nM, demonstrating significant potency and minimal off-target effects on RIPK3 (IC50 > 10,000 nM). This compound provides substantial neuroprotection by preventing the phosphorylation of key proteins involved in the necroptosis pathway, including RIPK1, RIPK3, and MLKL. Notably, RIPK1-IN-34 exhibits neuroprotective effects in the rat middle cerebral artery occlusion (MCAO) model, making it a valuable tool for research focused on mitigating damage in acute ischemic stroke (AIS). -
RIPK1 Inhibitor
RIPK1-IN-16 is a potent, orally active inhibitor of Receptor-Interacting Protein Kinase 1 (RIPK1). It effectively mitigates excessive inflammation by blocking RIPK1-mediated necroptosis. This compound demonstrates protective effects in mouse models against tumor necrosis factor (TNF)-induced systemic inflammatory response syndrome and sepsis, making it a valuable tool for research into inflammatory diseases and cell death pathways. -
RIPK1 Kinase Inhibitor
RIPK1-IN-20 is a potent inhibitor targeting RIPK1 kinase, exhibiting significant enzymatic inhibition with an IC50 value of 59.8 nM. This compound effectively blocks TNFα-induced necroptosis in both human and murine cells, demonstrating EC50 values ranging from 1.06 to 4.58 nM. It serves as a valuable tool for research into cell death pathways and therapeutic interventions in necroptotic diseases. -
RIPK1 Inhibitor
RIPK1-IN-9 is a selective inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). It demonstrates potent inhibitory activity in U937 cells with an IC50 of 2 nM, and in L929 cells with an IC50 of 1.3 nM. This compound is valuable for research in cell death, inflammation, and various diseases where RIPK1 is implicated. -
RIPK1 Inhibitor
RIPK1-IN-10 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1), a key regulator of cellular apoptosis and necroptosis. This compound is designed for use in biological research applications, particularly in studies focused on cell death pathways, inflammatory responses, and neurodegenerative diseases. Its inhibition of RIPK1 provides a valuable tool for investigating the therapeutic potential of modulating necroptotic processes in various disease models.
